Amyloid plaques are pathological hallmarks of Alzheimer’s disease (AD) — clumps of misfolded proteins that accumulate in the brain, disrupting and killing neurons and resulting in the progressive cognitive impairment that is characteristic of the widespread neurological disorder. In animal models, a new compound modulated a key enzyme, reducing or eliminating production of these problematic protein fragments.
Read on